Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG x CD20)

doi:10.1186/s12645-023-00230-6

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 藥學系(所) > 期刊論文 > Item 310902800/34785

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34785

標題:	Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG x CD20)
作者:	Chen, Huei-Jen Cheng, Yi-An Chen, Yu-Tung Li, Chia-Ching Huang, Bo-Cheng Hong, Shih-Ting Chen, I. -Ju Ho, Kai-Wen Chen, Chiao-Yun Chen, Fang-Ming Wang, Jaw-Yuan Roffler, Steve R. Cheng, Tian-Lu Wu, Dung-Ho
貢獻者:	Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol Kaohsiung Med Univ, Grad Inst Med, Coll Med Kaohsiung Med Univ, Drug Dev & Value Creat Res Ctr Kaohsiung Med Univ Hosp, Dept Med Res Kaohsiung Med Univ Hosp, Dept Med Imaging Kaohsiung Med Univ, Coll Med, Sch Postbaccalaureate Med Kaohsiung Med Univ Hosp, Dept Surg, Div Breast Oncol & Surg Kaohsiung Municipal Tatung Hosp, Dept Gen Surg Kaohsiung Med Univ, Coll Med, Fac Med, Dept Surg Acad Sinica, Inst Biomed Sci Chia Nan Univ Pharm & Sci I Shou Univ, Sch Chinese Med Postbaccalaureate
關鍵字:	PEGylated nanoparticles (PEG-NPs) Enhanced permeability and retention effect (EPR effect) Anti-PEG bispecific antibody (BsAb mPEG x CD20) CD20-armed liposomes alpha CD20/PLD Hematologic malignancies
日期:	2023
上傳時間:	2024-12-24 18:00:05 (UTC+8)
出版者:	SPRINGER WIEN
摘要:	Background: PEGylated nanoparticles (PEG-NPs) are not effective for hematologic malignancies as they lack the enhanced permeability and retention effect (EPR effect). Tumor-targeted PEG-NPs can systemically track lymphoma and actively internalize into cancer cells to enhance therapeutic efficacy. We generated an anti-PEG bispecific antibody (BsAb; mPEG x CD20) which was able to simultaneously bind to methoxy PEG on liposomes and CD20 to form multivalent alpha CD20-armed liposomes. This alpha CD20-armed liposome was able to crosslink CD20 on lymphoma cells to enhance cellular internalization and the anti-cancer efficacy of the liposomes to lymphoma. We generated mPEG x CD20 and used this bispecific antibody to modify PEGylated liposomal doxorubicin (PLD) through a one-step formulation.Results: alpha CD20-armed PLD (alpha CD20/PLD) specifically targeted CD20+ Raji cells and enhanced PLD internalization 56-fold after 24 h. alpha CD20/PLD also increased cytotoxicity to Raji cells by 15.2-fold in comparison with PLD and control mPEG x DNS-modified PLD (alpha DNS/PLD). mPEG x CD20 significantly enhanced the tumor accumulation 2.8-fold in comparison with mPEG x DNS-conjugated PEGylated liposomal DiD in Raji tumors. Moreover, alpha CD20/PLD had significantly greater therapeutic efficacy as compared to alpha DNS/PLD (P < 0.0001) and PLD(P < 0.0001), and alpha CD20/PLD-treated mice had a 90% survival rate at 100-day post-treatment.Conclusions: Modification of mPEG x CD20 can confer PLD with CD20 specificity to enhance the internalization and the anti-cancer efficacy of PEG-NPs. This therapeutic strategy can conveniently be used to modify various PEG-NPs with anti-PEG BsAb to overcome the lack of EPR effect of hematologic malignancies and improve therapeutic efficacy.
關聯:	Cancer Nanotechnology, v.14, n.1, Article 78
顯示於類別:	[藥學系(所)] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	22	檢視/開啟
s12645-023-00230-6.pdf		1427Kb	Adobe PDF	7	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....